drugset / Trial / NCT04005144
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
Phase 1
Terminated
3 enrolled
University of California, San Francisco
Array BioPharma · collabTakeda · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of brigatinib and binimetinib in treating patients with stage IIIB-IV non-small cell lung cancer and a type of gene mutation called a rearrangement in the ALK or ROS1 genes. Brigatinib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2020-02-25
- Primary completion
- 2022-10-01
- Completion
- 2022-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | — | Oral |
| Subject | Brigatinib | Small molecule | — | Oral |